Diagnosis and reversal of multidrug resistance in paediatric cancers

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 1051-1061

  Chan, H S L ^a   Grogan, T M ^b   DeBoer, G ^c   Haddad, G ^a   Gallie, B L ^a   Ling, V ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF ARIZONA   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE; GLYCOPROTEIN P;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RESISTANCE; CHILDHOOD CANCER; CHILDHOOD MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; NEUROBLASTOMA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RETINOBLASTOMA; REVIEW; RHABDOMYOSARCOMA;

BONE NEOPLASMS; CHILD; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEUROBLASTOMA; OSTEOSARCOMA; P-GLYCOPROTEIN; RHABDOMYOSARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 0029939666     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00085-8     Document Type: Article

References (153)

1. Young JL Jr, Ries LG, Silverberg E, Horm JW, Miller RW. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 1986, 58, 598-602.
2. Chan HSL, Erlichman C. Cancer chemotherapy in pediatric malignancies. In Radde IC, MacLeod SM, eds. Pediatric Pharmacology and Therapeutics. St. Louis, Mosby-Year Book Inc, 1993, 515-529.
3. Chabner BA. Karnofsky Memorial Lecture. The oncologic end game. J Clin Oncol 1986, 4, 626-638.
4. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455, 152-162.
5. Beck WT. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 1989, 81, 1683-1685.
6. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54, 4313-4320.
7. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
8. (r) 110,000 vesicular protein in non-Pgp-mediated multidrug resistance. Cancer Res 1993, 53, 1475-1479.
9. Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 1986, 5, 25-46.
10. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of Pgp and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989, 7, 415-424.
11. Bourhis J, Bénard J, Hartmann O, Boccon-Gibod L, Lemerle J, Riou G. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 1989, 81, 1401-1405.
12. Goldstein LG, Fojo AT, Ueda K, et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990, 8, 128-136.
13. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. Pgp expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991, 9, 17-24.
14. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of Pgp: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990, 8, 689-704.
15. Chan HSL, Haddad G, Thorner PS, et al. Pgp expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991, 325, 1608-1614.
16. Chan HSL, Haddad G, Thorner PS, DeBoer G, Ling V. Multidrug resistance in childhood malignancies. In Fortner JG, Rhoads JE, eds. Accomplishments in Cancer Research 1991, General Motors Cancer Research Foundation. Philadelphia, J.B. Lippincott, 1992, 184-216.
17. Sato H, Preisler H, Day R, et al. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 1990, 75, 340-345.
18. Marie J-P, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991, 78, 586-592.
19. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83, 708-712.
20. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance Pgp expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 1992, 79, 473-476.
21. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993, 7, 825-831.
22. Cheng A-l, Su I-j, Chen Y-c, Lee T-c, Wang C-h. Expression of Pgp and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993, 11, 109-115.
23. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated Pgp (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993, 81, 2394-2398.
24. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry 1994, 17, 84-93.
25. Lamy T, Goasguen JE, Mordelet E, et al. Pgp (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994, 8, 1879-1883.
26. Lamy T, Drenou B, Grulois I, et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995, 9, 1549-1555.
27. Gerlach JH, Endicott JA, Juranka PF, et al. Homology between Pgp and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986, 324, 485-489.
28. Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986, 47, 371-380.
29. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (Pgp) gene from multidrug-resistant human cells. Cell 1986, 47, 381-389.
30. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 1987, 84, 265-269.
31. Cordon-Cardo C, O'Brien JP, Casals D, et al. Mutidrug-resistance gene (Pgp) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86, 695-698.
32. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (Pgp) in human normal and tumor tissues. J Histochem Cytochem 1990, 38, 1277-1287.
33. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. Pgps in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990, 21, 34-48.
34. Chaudhary PM, Roninson IB. Expression and activity of Pgp, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66, 85-94.
35. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance Pgp in human peripheral blood lymphocytes. Blood 1992, 80, 2735-2739.
36. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992, 80, 2729-2734.
37. Hegewisch-Becker S, Fleigner M, Tsuruo T, Zander A, Zeller W, Hossfeld DK. Pgp expression in normal and reactive bone marrows. Br J Cancer 1993, 67, 430-435.
38. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. Pgp expression and function in circulating blood cells from normal volunteers. Blood 1994, 83, 2451-2458.
39. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V. Identification of members of the Pgp multigene family. Mol Cell Biol 1989, 9, 1224-1232.
40. Gros P, Raymond M, Bell J, Housman D. Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 1988, 8, 2770-2778.
41. Smit JJM, Schinkel AH, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 Pgp gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75, 451-462.
42. Schinkel AH, Smit JJM, Van Tellingen O, et al. Disruption of the mouse mdrla Pgp gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
43. Nooter K, Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br J Cancer 1991, 63, 663-669.
44. Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesman MM. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987, 5, 1922-1927.
45. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (Pgp) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51, 2720-2726.
46. Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V. Detection of Pgp in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985, 3, 311-315.
47. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M. Immunohistochemical analysis of Pgp expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990, 21, 787-791.
48. Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance Pgp in breast carcinoma. J Natl Cancer Inst 1991, 83, 111-116.
49. Gsur A, Zochbauer S, Gotzl M, Kyrle PA, Lechner K, Pirker R. MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. Leuk Lymphoma 1993, 12, 91-94.
50. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993, 11, 1629-1635.
51. Zhou DC, Hoang-Ngoc L, Delmer A, et al. Expression of resistance genes in acute leukemia. Leuk Lymphoma 1994, 13 (Suppl. 1), 27-30.
52. Chan HSL, Thorner PS, Haddad G, Gallie BL. Multidrug-resistant phenotype in retinoblastoma correlates with Pgp expression. Ophthalmology 1991, 98, 1425-1431.
53. Chan HSL, Thorner PS, Haddad G, Gallie BL. Effect of chemotherapy on intraocular retinoblastoma. Int J Pediatr Hematol Oncol 1995, 2, 269-281.
54. Yahanda AM, Alder KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992, 10, 1624-1634.
55. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992, 10, 1635-1642.
56. Sonneveld P, Durie BG, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. The Lancet 1992, 340, 255-259.
57. Chan HSL, Thorner PS, Weitzman SS, et al. Cyclosporin A for reversal of mutidrug resistance in childhood malignancies. Proc Am Assoc Cancer Res 1992, 33, 478 (Abstr. 2854).
58. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993, 53, 4837-4842.
59. Samuels BL, Mick R, Vogelzang NJ, et al. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther 1993, 54, 421-429.
60. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993, 11, 1652-1660.
61. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994, 12, 835-842.
62. Cowie FJ, Pinkerton CR, Phillips M, et al. Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 1995, 71, 877-881.
63. Dalton WS, Crowley JJ, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995, 75, 815-820.
64. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13, 1995-2004.
65. Favrot M, Combaret V, Goillot E, et al. Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br JCancer 1991, 64, 233-238.
66. Nakagawara A, Kadomatsu K, Sato S, et al. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 1990, 50, 3043-3047.
67. Bates SE, Shieh CY, Tsokos M. Expression of mdr-1/P-glycoprotein in human neuroblastoma. Am J Pathol 1991, 139, 305-315.
68. Niehans GA, Jaszcz W, Brunetto V, et al. Immunohistochemical identification of Pgp in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992, 52, 3768-3775.
69. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993, 82, 1288-1299.
70. Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M. Immunohistochemical detection of Pgp in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 1994, 102, 61-67.
71. Goldstein LJ, Galski H, Fojo AT, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81, 116-124.
72. Bradley G, Naik M, Ling V. Pgp expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res 1989, 49, 2790-2796.
73. Noonan KE, Beck C, HolzmayerTA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87, 7160-7164.
74. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993, 213, 414-421.
75. Gerlach JH, Bell DR, Karakousis C, et al. Pgp in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987, 5, 1452-1460.
76. Baker RM, Fredericks WJ, Chen Y, et al. Detection of Pgp in human tumors by immunoblot analyses. In Mihich E, ed. Drug Resistance: Mechanisms and Reversal. Pezcoller Foundation Symposia, Trento, Italy. Rome, John Libby CIC, 1989, 167-180.
77. Pilarski LM, Paine D, McElhaney JE, Cass CE, Belch AR. Multidrug transporter Pgp 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. Am J Hematol 1995, 49, 323-335.
78. Leith CP, Chen IM, Kopecky KJ, et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux-cases. Blood 1995, 86, 2329-2342.
79. Paietta E, Andersen J, Racevskis J, Ashigbi M, Cassileth P, Wiernik PH. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Blood Rev 1995, 9, 47-52.
80. Broxterman HJ, Feller N, Kuiper CM, et al. Correlation between functional and molecular analysis of mdr1 Pgp in human solid-tumor xenografts. Im J Cancer 1995, 61, 880-886.
81. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein Pl 70: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989, 37, 159-164.
82. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994, 54, 1536-1541.
83. Willingham MC, Riehert ND, Cornwell MM, et al. Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem 1987, 35, 1451-1456.
84. Grogan T, Dalton W, Rybski J, et al. Optimization of immunocytochemical Pgp assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 1990, 63, 815-824.
85. Pirker R, Wallner J, Gsur A, et al. MDR1 gene expression in primary colorectal carcinomas. Br J Cancer 1993, 68, 691-694.
86. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (Pgp) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992, 84, 1486-1491.
87. Wunder JS, Bell RS, Wold L, Andrulis IL. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthopaed Res 1993, 11, 396-403.
88. Kang Y-K, Zhan Z, Regis J, et al. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995, 86, 1515-1524.
89. Pollard-Knight D, Read CA, Downes MJ, et al. Nonradioactive nucleic acid detection by enhanced chemiluminescence using probes directly labeled with horseradish peroxidase. Anal Biochem 1990, 185, 84-89.
90. Friedlander ML, Bell DR, Leary J, Davey RA. Comparison of western blot analysis and immunocytochemical detection of Pgp in multidrug resistant cells. J Clin Pathol 1989, 42, 719-722.
91. Gala JL, McLachlan JM, Bell DR, Michaux JL, Ma DDF. Specificity and sensitivity of immunocytochemistry for detecting Pgp in haematological malignancies. J Clin Pathol 1994, 47, 619-624.
92. Lehne G, De Angelis P, Clausen OPF, Egeland T, Tsuruo T, Rugstad HE. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product Pgp. Cytometry 1995, 20, 228-237.
93. Longo R, Bensi L, Vecchi A, Messora C, Sacchi S. Pgp expression in acute myeloblastic leukemia analyzed by immunocytochemistry and flow cytometry. Leuk Lymphoma 1995, 17, 121-125.
94. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994, 12, 1584-1591.
95. Campos L, Guyotat D, Jaffar C, Solary E, Archimbaud E, Treille D. Correlation of MDR1/P-170 expression with dauno-rubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Eur J Haematol 1992, 48, 254-258.
96. Bailly J-D, Muller C, Jaffrézou J-P, et al. Lack of correlation between expression and function of Pgp in acute myeloid leukemia cell lines. Leukemia 1995, 9, 799-807.
97. Xie XY, Robb D, Chow S, Hedley DW. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia 1995, 9, 1882-1887.
98. Brophy NA, Marie JP, Rojas VA, et al. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia 1994, 8, 327-335.
99. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of Pgp in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985, 316, 820-823.
100. Tsuruo T, Sugimoto Y, Hamada H, et al. Detection of multidrug resistance markers, Pgp and mdr1 mRNA, in human leukemia cells. Jpn J Cancer Res 1987, 78, 1415-1419.
101. Georges E, Bradley G, Gariepy J, Ling V. Detection of Pgp isoforms by gene-specific monoclonal antibodies. Prod Natl Acad Sci USA 1990, 87, 152-156.
102. Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG. Reversal of vinca alkaloid resistance by anti-Pgp monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 1992, 52, 1810-1816.
103. Mechetner EB, Roninson IB. Efficient inhibition of Pgp-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992, 89, 5824-5828.
104. Arceci RJ, Stieglitz K, Bras J, Schinkel A, Baas F, Croop J. Monoclonal antibody to an external epitope of the human mdr1 Pgp. Cancer Res 1993, 53, 310-317.
105. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
106. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient II. Analysis and examples. Br J Cancer 1977, 35, 1-39.
107. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factor in neuroblastoma. Cancer 1987, 59, 1853-1859.
108. Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St Jude Children's Research Hospital experience, 1962 to 1988. J Clin Oncol 1991, 9, 1599-1608.
109. Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991, 9, 1037-1044.
110. Laug WE, Siegel SE, Shaw KNF, Landing B, Baptista J, Gutenstein M. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978, 62, 77-83.
111. Hann HW, Evans AE, Cohen IJ, Leitmeyer JE. Biologic differences between neuroblastoma stages IV-S and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med 1981, 305, 425-429.
112. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984, 73, 405-416.
113. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313, 1111-1116.
114. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984, 311, 231-235.
115. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995, 24, 215-221.
116. Zeltzer PM, Marangos PJ, Parma AM, et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. The Lancet 1983, 2, 361-363.
117. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993, 328, 847-854.
118. Kogner P, Bjork O, Theodorsson E. Neuropeptide Y in neuroblastoma: increased concentration in metastasis, released during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol 1993, 21, 317-322.
119. Leone A, Seeger RC, Hong CM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993, 8, 855-865.
120. Krajewski S, Chatten J, Hanada M, Reed JC. Immunohistochemical analysis of the Bc1-2 oncoprotein in human neuroblastomas: comparisons with tumor cell differentiation and N-Myc protein. Lab Invest 1995, 72, 42-54.
121. Chan HSL, Haddad G, DeBoer G, Gallie BL, Ling V. Multidrug resistance in pediatric malignancies. In Fisher GA, Sikic BI, eds. Drug Resistance in Clinical Oncology and Hematology, Vol. 9. Philadelphia, W.B. Saunders, 1995, 275-318.
122. Chan HSL, Bradley G, Thorner P, Haddad G, Gallie BL, Ling V. A sensitive method for immunocytochemical detection of Pgp in multidrug-resistant human ovarian carcinoma cell lines. Lab Invest 1988, 59, 870-875.
123. Corrias MV, Di Martino D, Tonini GP, Cornaglia-Ferraris P. N-myc and MDR1 expression are mutually exclusive in NB tumors at onset. In Evans AE, D'Angio GJ, Knudson AG Jr, Seeger RC, eds. Advances in Neuroblastoma Research 3, Vol. 366. New York, Wiley-Liss Inc, 1991, 77-83.
124. O'Meara A, Imamura A, Johnson P, et al. Reactivity of Pgp monoclonal antibodies in childhood cancers. Oncology 1992, 49, 203-208.
125. Gaiger AM, Soule EH, Newton WA, Jr. Pathology of rhabdomyosarcoma: experience of the Intergroup Rhabdomyosarcoma Study. NCI Monogr 1981, 56, 19-27.
126. Gehan EA, Glover FN, Maurer HM, et al. Prognostic factors in children with rhabdomyosarcoma. NCI Monogr 1981, 56, 83-92.
127. Grist WM, Garnsey L, Beltangady MS, et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol 1990, 8, 443-452.
128. Link MP. Preoperative and adjuvant chemotherapy in osteosarcoma. In Novak JF, McMaster JH, eds. Frontiers of Osteosarcoma Research. Kirkland, Hogrefe and Huber Publishers, 1993, 41-49.
129. Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 1972, 4, 482-510.
130. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986, 314, 1600-1606.
131. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Ortho Related Res 1991, 270, 8-14.
132. Taylor WF, Ivsin JC, Unni KK, Beabout JW, Golenzer HJ, Black LE. Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst 1989, 81, 21-30.
133. Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 1991, 51, 5417-5424.
134. Holm PS, Scanlon KJ, Dietel M. Reversion of multidrug resistance in the Pgp-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 1994, 70, 239-243.
135. Ihnat MA, Hamilton JW. Suppression of multidrug resistance gene rndrlb mRNA and Pgp expression by mitomycin C in rat H4IIE cells [Abstract]. Proc Am Assoc Cancer Res 1995, 36, A2056.
136. FitzGerald DJ, Willingham MC, Cardarelli CO, et al. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 1987, 84, 4288-4292.
137. Hamada H, Tsuruo T. Functional role of the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986, 83, 7785-7789.
138. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41, 1967-1972.
139. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986, 77, 1405-1408.
140. Slater LM, Murray SL, Wetzel MW, Wisdom RM, DuVall EM. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest 1982, 70, 1131-1134.
141. Slater LM, Murray SL, Wetzel MW, Sweet P, Stupecky M. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol 1986, 16, 50-54.
142. Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. BrJ Cancer 1986, 54, 235-238.
143. Slater L, Sweet P, Wetzel M, Stupecky M, Osann K. Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leukemia Res 1995, 19, 543-548.
144. Verweij J, Herweijer H, Oosterom R, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 1991, 64, 361-364.
145. Warner E, Tobe SW, Andrulis IL, Pei Y, Trachtenberg J, Skorecki KL. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol 1995, 18, 251-256.
146. Chabner BA, Fojo A. Multidrug resistance: Pgp and its allies -the elusive foes. J Natl Cancer Inst 1989, 81, 910-913.
147. Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995, 13, 1985-1994.
148. Cowie F, Pinkerton CR. Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance. J Clin Oncol 1994, 12, 1998-1999.
149. Chan HSL, Canton MD, Gallie BL. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res 1989, 9, 469-474.
150. Chan HSL, DeBoer G, Koren, G, et al. Cyclosporin-A-modulated chemotherapy with focal therapy: a new approach to retinoblastoma. Proc Am Assoc Cancer Res 1994, 35, 359 (Abstract 2138).
151. Abramson DH, Ellsworth RM, Tretter P, Adams K, Kitchin FD. Simultaneous bilateral radiation for advanced bilateral retinoblastoma. Arch Ophthalmol 1981, 99, 1763-1766.
152. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988, 121-141.
153. Longo DL, Duffey PL, DeVita VT Jr, Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991, 9, 2042-2051.